Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Seagan Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, PIHONAK, SARAH, who is also the busiest examiner for the company. The presence of 1 pending action indicates a focused prosecution effort at this time.
The portfolio's current activity is confined to 1 distinct art unit. PIHONAK, SARAH is the busiest examiner for the company, with 1 pending action. This concentration in 1 distinct art unit under a single examiner suggests that the company's immediate patent success is tied to a specific point of review. Practitioners should focus on the examination style of PIHONAK, SARAH, as there are no other art units or examiners to provide a baseline for comparison within the current Biotechnology & Pharmaceuticals portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIHONAK, SARAH | 1 | 61.4% | +42.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18185341 | CAMPTOTHECIN CONJUGATES | PIHONAK, SARAH | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18185341 | CAMPTOTHECIN CONJUGATES | PIHONAK, SARAH | 1627 | §112 | Final Rejection | — | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeagan Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sarah Pihonak has the most, with 1 of Seagan Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.